Analysis of Protein C Inhibitor/ SERPINA5

Year 2020, , 75 - 79, 26.02.2020

Didem Özkan , Nejat Akar

https://doi.org/10.18663/tjcl.645392

Cited By: 2

Abstract

Protein C inhibitor is a non-specific serine protease inhibitor with extensive protease reactivity. Protein C inhibitor (SERPINA5, plasminogen activator inhibitor-3/PAI-3) is a secreted, extracellular clade A serpin. SERPINA5/PCI has originally been described as an inhibitor of activated protein C and independently as an inhibitor of the plasminogen activator urokinase. SERPINA5 binds glycosaminoglycans, phospholipids, and retinoic acid. Glycosaminoglycans and certain phospholipids can modulate its inhibitory activity and specificity.  PCI plays role at thrombosis and fibrinolysis, regulation of fertilization, tissue regeneration, vascular permeability, tumor development, invasion, metastasis and angiogenesis. In this review; aimed  to provide information about the functions of PCI and to provide guidance for studies.

Keywords

Protein C Inhibitor, SERPINA5

Protein C İnhibitörü/SERPİNA5 analizi

Abstract

Protein C inhibitörü (PCI), serin
proteaz ailesinden (SERPINA5) α1 proteaz inhibitiör prototipinde bir plazma
glikoproteinidir. İlk olarak insan plazmasında aktive protein C inhibitörü
olarak daha sonra ise koagülasyon ve fibrinolizisin inhibitörü olarak
tanımlanmıştır. PCI, idrardan sekrete olur ve ürokinaz tipi plazminojen
aktivatörü (uPA) ile kompleks oluşturur.  Bu nedenle plazminojen aktivatör inhibitörü 3
(PAI-3) olarak da bilinir. PCI’nın tromboz ve fibrinoliziste, fertilizasyonun
düzenlenmesinde, doku rejenerasyonunda, vasküler permeabilitede, tümör gelişimi,
invazyon, metastaz ve anjiyogenezin düzenlenmesinde rol oynadığı bilinmektedir Bu derlemede; PCI'ın işlevleri hakkında bilgi vermek ve ileride yapılacak çalışmalar
için rehberlik sağlamak amaçlanmıştır.

Keywords

Protein C, SERPINA5

References

• 1. Meijers JC, Kanters DH, Vlooswijk RA, van Erp HE, Hessing M, Bouma BN. Inactivation of human plasma kallikrein and factor XIa by protein C inhibitor. Biochemistry 1988; 27: 4231–7
• 2. Suzuki K. Activated protein C inhibitor. Semin Thromb Hemost 1984; 10: 154–61
• 3. Hayashi T, Nishioka J, Kamada H, Hamada K, Fujii K, Naka D, Nagaike K, Uemoto S, Kobayashi T, Hattori A, Suzuk K. Protein C inhibitor directly and potently inhibits activated hepatocyte growth factor activator. J Thromb Haemost 2007; 5: 1477–85.
• 4. Li W, Adams TE, Kjellberg M, Stenflo J, Huntington JA. Structure of native protein C inhibitor provides insight into its multiple functions. J Biol Chem 2007; 282: 13759–68
• 5. Esmon CT. Inflammation and the activated protein C anticoagulant pathway. Semin Thromb Hemost 2006; 1: 49-60
• 6. Espana F, Medina P, Navarro S, Zorio E, Estellés A, Aznar J. The multifunctional protein C system. Curr Med Chem Cardiovasc Hematol Agents 2005; 3: 119-31
• 7. Tran S, Dahlbäck B. Novel APC-cleavage sites in FVa provide insights into mechanisms of action of APC and its cofactor protein S. J Thromb Haemost 2010; 8: 129-36.
• 8. Dahlbäck B. The discovery of activated protein C resistance. J Thromb Haemost 2003; 1: 3–9
• 9. Nicolaes GA, Dahlbäck B. Congenital and acquired activated protein C resistance. Semin Vasc Med 2003; 3: 33–46.
• 10. Akar N. Factor V 1691 G-A mutation distribution in healthy Turkish population. Turk J Hematol; 2009; 26: 9-11
• 11. Kemkes-Matthes B. Heterozygous protein C deficiency type 1. 1989; 58; 201-06
• 12. Esmon CT. Anticoagulant Protein C/ Thrombomodulin Pathway. The Online Metabolic & Molecular Bases of Inherited Disease; 2001; 4327–38.
• 13. Lannan KL, Phipss RP, White RJ. Thrombosis, Platelets, Microparticles and PAH: more than a clot. Drug Discovery Today; 2014; 1230-35
• 14. Nishii Y, Gabazza EC, Fujimoto H et al. Protective role of protein C inhibitor in monocrotaline-induced pulmonary hypertension. J Thromb Haemost 2006; 4: 2331–39
• 15. Akar N, Arsan S, Deda G, Fitöz S, Soneltur B, Uysal Z. Pediatrik inme. Ankara: Çocuk Hastalıkları Araştırma Vakfı Yayını, 2005, Ankara
• 16. Fukudome, K. Esmon, C. T. Identification, cloning, and regulation of a novel endothelial cell protein C/activated protein C receptor. J Biol Chem 1994; 269; 26486-91.
• 17. Stief TW, Radtke KP, Heimburger N.Inhibition of urokinase by protein-C inhibitor (PCI): Evidence for identity of PCI and plasminogen activator inhibitor -3. Biol Chem Hoppe-Syler 1987; 368:1427-33
• 18. Suzuki K. The multi-funstional serpin, protein C inhibitor: beyond thrombosis and hemostasis. J Thromb Hemost 2008; 6: 2017-26
• 19. Meijers JCM, Herwald H. Protein C Inhibitor. Seminars in Thromb Hemost 2011; 37; 4; 349-54
• 20. Geiger M. Protein C inhibitor, a serpin with functions in- and outside vascular biology. Thromb Haemost 2007; 97: 343–47
• 21. G. Van Raemdonck et al. Increased Serpin A5 levels in the cervicovaginal fluid of HIV-1 exposed seronegatives suggest that a subtle balance between serine proteases and their inhibitors may determine susceptibility to HIV-1 infection,. Virology 2014; 458–459: 11–21
• 22. Wagenaar GTM, Uhrin P, Weipoltshammer K et al. Expression patterns of protein C inhibitor in mouse development. J Mol Histol 2010; 41: 27–37
• 23. Hayashi T, Nishioka J, Nakagawa N et al. Protein C inhibitor directly and potently inhibits activated hepatocyte growth factor activator. J Thromb Haemost 2007; 5: 1477–85
• 24. Espana F, Vicente V, Tabernero D, Scharrer I, Griffin JH. Determination of plasma protein C inhibitor and of two activated protein C-inhibitor complexes in normals and in patients with intravascular coagulation and thrombotic disease. Thromb Res 1990; 59: 593–608
• 25. Uhrin P, Scho¨fer C, Zaujec J et al. Male fertility and protein C inhibitor/plasminogen activator inhibitor-3 (PCI): localization of PCI in mouse testis and failure of single plasminogen activator knockout to restore spermatogenesisin PCI-deficient mice. Fertil Steril 2007; 88: 1049–57
• 26. Gianotten J, Schimmel AW, van der Veen F, Lombardi MP, Meijers JCM. Absence of mutations in the PCI gene in subfertile men. Mol Hum Reprod 2004; 10: 807–13
• 27. Bungum M, Giwercman A, Bungum L, Humaidan P, Rastkhani H, Giwercman YL. Polymorphisms in the protein C inhibitor gene in in vitro fertilization failure. Fertil Steril 2010; 93: 277-79.
• 28. Hamada T, Kamada H, Hayashi T et al. Protein C inhibitor regulates hepatocyte growth factor activator-mediated liver regeneration in mice. Gut 2008; 57: 365–73
• 29. Han MH, Hwang SI, Roy DB et al. Proteomic analysis of active multiple sclerosis lesions reveals therapeutic targets. Nature 2008; 451: 1076–81
• 30. Rosenzweig CN, Zhang Z, Sun X et al. Predicting prostate cancer biochemical recurrence using a panel of serum proteomic biomarkers. J Urol 2009; 181: 1407–14
• 31. Suzuki K, Hayashi T. Protein C and its inhibitor in malignancy. Semin Thromb Hemost 2007; 33: 667–72
• 32.Suzuki K, Deyashiki Y, Nishioka J, Kurachi K, Akira M, YamamotoS, Hashimoto S. Characterization of a cDNA for human protein C inhibitor. A new member of the plasma serine protease inhibitor superfamily. J Biol Chem 1997; 262: 611–16.
• 33.Torun D, Deda G, Ertem M, Uysal Z, Yılmaz E, Akar N. A novel protein C inhibitor gene mutation in pediatric stroke patients after bone marrow transplantation. Mol Bio Rep 2013; 40: 5465-68